Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses whether finasteride's reduction of DHT and increase in scalp testosterone contribute to hair follicle miniaturization. Some participants argue testosterone does not cause miniaturization, while others suggest that even with reduced DHT, other androgens like testosterone may still contribute to hair loss.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The user experienced stable hairline but diffuse thinning after switching from oral finasteride to a topical solution of minoxidil and finasteride. They are concerned about the effectiveness of the topical treatment and are considering other options due to a recent decline in hair density.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

The user is experiencing diffuse shedding but also hairline regrowth after starting finasteride, switching to dutasteride, and using oral minoxidil, ketoconazole shampoo, and RU58841. Other users advise patience, suggesting that the treatments need more time to show results and caution against using too many medications simultaneously.

The conversation is about a user experiencing hair shedding after switching from finasteride to dutasteride and increasing their oral minoxidil dose. The user is advised to continue with the current treatment, consider adding topical minoxidil, and consult a dermatologist for potential underlying issues.

The user started using topical finasteride 0.025% and minoxidil 5% twice daily, seeing initial improvement but later experiencing shedding and scalp pain. They are considering increasing the finasteride dose to 0.05% while using keto shampoo and dermarolling, and are debating the effectiveness of low versus standard doses of finasteride.

The conversation discusses a hair loss treatment regimen involving high doses of dutasteride, finasteride, and minoxidil, with concerns about safety and potential side effects. Users advise against the excessive use of these medications, suggesting more moderate approaches and consulting a doctor.

After 2 years of using finasteride and minoxidil with good results, the user is experiencing severe scalp itchiness, shedding, and tenderness. Despite dermatologists finding nothing wrong, the user seeks over-the-counter treatments for the itch.

User "Number_Worried00" is using a treatment stack for hair loss, including Minoxidil, Finasteride, Dutasteride, Estradiol, Cetirizine, and Pyrilutamide. Another user suggests that if the cause is vitamin deficiency or inflammation, the stack may not be effective.

The user experienced prolonged hair shedding after restarting oral minoxidil (OM) at 2.5 mg in September 2023, following a break due to hypertrichosis. Despite seeing regrowth, the shedding has not decreased after 11 weeks on the increased dosage.

RU58841 stopped shedding after two weeks and improved hair after eight months. Initial thinning may occur within the first month.

A 34-year-old male started using 5% minoxidil foam for hair loss and experienced shedding, which is a normal part of the process. He is considering adding finasteride to his regimen but is concerned about potential side effects, particularly sexual performance issues.

The user has been using Finasteride for hair loss and is considering adding alphatradiol, stemoxydine, or 2% minoxidil to their regimen. They are concerned that stemoxydine, which shortens the resting phase of hair, might accelerate hair loss in those not using Finasteride by depleting hair cycles without strengthening miniaturized hairs.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

Foligain Shampoo might be causing increased hair loss compared to Vichy shampoo. The user is seeking feedback on others' experiences with Foligain.

The user experienced significant hair improvement using finasteride, minoxidil, ketoconazole shampoo, and microneedling over a year, with no side effects. They used topical minoxidil and reported shedding phases, but no current shedding as of March 2026.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The user is considering using 2 vials of Fluridil every other day instead of 1 vial daily for better scalp coverage. They are questioning if this method would be as effective.

The conversation is about the side effects of finasteride, including Post Finasteride Syndrome, with varied personal experiences and differing views on the credibility of information sources. Some participants also discuss using minoxidil as a hair loss treatment.

The conversation is about long-term finasteride use for hair loss, with users discussing periods of improvement and worsening, and considering switching to dutasteride. Other treatments mentioned include minoxidil, red light therapy, microneedling, and scalp massaging.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Finasteride worked better for frontal scalp hair loss, while dutasteride helped the crown and mid-scalp but worsened the frontal area. The user shared personal experiences and invited open dialogue.

Finasteride may cause initial shedding, but it's part of the process for stronger hair growth. Users suggest starting treatment and trusting the process, as it can improve hair density over time.

Dutasteride improved hair density and thickness in men who didn't respond to finasteride, with some experiencing transient sexual dysfunction. Users discussed switching from finasteride to dutasteride, noting initial shedding but eventual hair improvement.

A user experienced initial improvement with finasteride and minoxidil but is now losing progress and considering switching to dutasteride. Others suggest seasonal shedding, vitamin D deficiency, or trying dutasteride, while some share personal experiences with shedding cycles and treatment adjustments.

Switching from finasteride and topical minoxidil to oral minoxidil and dutasteride worsened hair condition, leading to frustration and heart issues, prompting a return to topical treatments and the addition of tretinoin. Patience and consistency are advised, as these treatments can take years to show results, and abrupt changes may cause shedding.

Monthly microneedling combined with low-dose topical dutasteride shows promising results for hair density and thickness with minimal side effects, especially in the frontal area. Despite its effectiveness, it is not widely discussed or used due to availability and cost concerns.